Synlogic EBITDA per osake

Mitä Synlogic tekee? Synlogic Inc is a clinical-stage biopharmaceutical company based in Cambridge, United States. The company's primary focus is on developing innovative therapies using its proprietary Synthetic Biotic development platform. Synlogic's pipeline includes programs targeting rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU), as well as other conditions including inflammatory bowel disease, cancer, and metabolic disorders like diabetes and obesity. The company's approach involves genetically reengineering probiotic microbes to perform or deliver critical functions impaired by disease. Synlogic went public via an IPO on September 30, 2015, and its stock is traded under the ticker symbol SYBX. The company's website is www.synlogictx.com. Synlogic is categorized under the Health Care sector within the Biotechnology industry. The company currently reports having 1 employee, though this figure may not align with the source description's mention of 76 full-time employees. The company's research and development efforts are centered on leveraging synthetic biology to create therapeutic solutions for complex medical conditions. Synlogic on yksi Eurpooliin suosituimmista yhtiöistä.